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INTRODUCTION
The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting dynamin-related protein 1. It further relates to methods of treating cancer which employ an inhibitor of dynamin-related protein 1 alone or together with a second antiproliferative agent.
BACKGROUND OF THE INVENTION
Mitochondria are dynamic organelles that consistently undergo fission and fusion events. Deficiencies in the proteins regulating mitochondrial dynamics are associated with a number of human pathologies including neurodegenerative diseases and newborn lethality (Westermann, 2010) . Recently, mitochondria have been shownto undergo morpho logical remodeling as cells progress through the cell cycle (Mitra et al., 2009) . At the G1/S boundary mitochondrial tubules form a highly fused network, which is associated with increased mitochondrial ATP production and high levels of cyclin E, in order to promote G1-to-S transition (Mitra et al., 2009 ). This hyperfused mitochondrial network is then disas sembled and becomes increasingly fragmented through S. G2 and M phase of the cell cycle, with the greatest fragmentation evident during mitosis in order to allow the proper partition ing of mitochondria between two daughter cells during cytokinesis (Kashatus et al., 2011) . Thus, mitochondrial remodeling throughout the cell cycle is considered to meet the cellular energy demands during the progression of specific stages of the cell cycle, and to ensure faithful inheritance of mitochondria during cell division. However, how deficiencies in the proteins that regulate mitochondrial dynamics impact cell cycle progression and hence directly contribute to the development of diseases is not clear.
The dynamic regulation of mitochondrial morphology is achieved by the coordination of mitochondrial fission and fusion events (Green and Van Houten, 2011) . Dynamin-re lated protein 1 (Drp1), a large dynamin-related GTPase, is essential for mitochondrial fission (Smirnova et al., 2001) . Loss of Drp1 results in elongated mitochondria, and Drp1 deficiencies have been identified in several human diseases (Cho et al., 2009; Wang et al., 2008 : Waterham et al., 2007 . Drp 1 is directly regulated by the machinery that controls cell cycle progression. For example, Drp1 is phosphorylated at Ser585 by cac2/cyclin B in order to promote mitochondrial fission during mitosis (Taguchi et al., 2007) . Drp1 deficiency is generally thought to cause mitochondrial dysfunction due to a failure of a Drpl-dependent mechanism of mitophagy that removes damaged mitochondria within the cell (Twig et al., 2008) . The resulting accumulation of damaged mitochon dria may lead to a depletion of cellular ATP and an inhibition of cell proliferation (Parone et al., 2008) . Such an energy depletion-related cell proliferation defect may be caused by a metabolic checkpoint that triggers an AMPK-and p53-de pendent G1/S cell cycle arrest (Jones et al., 2005; Owusu Ansah et al., 2008) . Consistent with such a mechanism, over expression of mutant Drp 1 (K38A), results in a hyperfused mitochondrial network and a p53-dependent delay of S phase entry (Mitra et al., 2009) . However, reduced cell proliferation has also been observed in the absence of cellular ATP deple tion in non-immortalized Drp1-knockout mouse embryonic fibroblasts (MEFs) (Wakabayashi et al., 2009 ). This suggests that defective mitochondrial dynamics may affect cell prolif eration through mechanisms that are not associated with mitochondrial energy metabolism.
Chiang et al. (2009) studied Drp-1 in lung adenocarci noma, and report a link between Drp 1 and chemotherapy drug resistance that is related to intracellular distribution of Drp 1, where sequestration of Drp 1 to the nucleus (which may be related to hypoxia) is associated with resistance to chemotherapy and poor prognosis.
United States Patent Application Publication Nos. US2005/0038051 and US2008/0287473, both by Nunnariet al., disclose mdivi-1 (referred to as compound A1 and mfisi-1 therein) and related compounds. These applications also dis close that mdivi-1 is a selective inhibitor of Dnm1, the yeast ortholog of Drp1, and inhibits mitochondrial fission and apo ptosis. Further, a polypeptide antagonist of calcineurin was reported to inhibit Drp1-dependent mitochondrial fragmen tation and apoptosis (Cereghetti and Scorrano, 2010).
SUMMARY OF THE INVENTION
The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp 1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp 1 inhibition results in a disruption of the cell cycle and DNA aberrancies; (ii) inhibition of both Drp 1 and ATR are synthetic lethal causing increased DNA damage and apo ptotic cell death; and (iii) even in resistant cell lines, Drp1 inhibitor (e.g., mdivi-1) together with a second antiprolifera tive agent (e.g., cisplatin) act synergistically to promote apo ptosis. Accordingly, the present invention provides for novel anticancer strategies. tion of mitochondrial respiration, depolarization of mito chondrial membrane potential or stimulation of mitochon drial ROS production does not induce G2/M cell cycle arrest oraneuploidy. MDA-MB-231 cells were treated with either 5 ug/ml oligomycin, 5uM FCCP, or 10 g/ml antimycin A for 24 h. Cell cycle distribution was determined as described FIG. 7. Loss of Drp1 induces replication stress-mediated genome instability. Our working model shows that mitochon drial hyperfusion induced by loss of fission protein Drp1 leads to replication stress, centrosome overduplication and chromosomal instability, which are mediated, at least in part, by aberrant expression of cyclin E in G2-phase. Persistent replication stress activates an ATM kinase signaling cascade that induces G2/M cell cycle checkpoint. This is consistent with our data that shows that knockdown of either the fusion protein Opal, cyclin E or ATM reverses the G2/M cell cycle arrest and aneuploidy observed in Drp1-deficient cells. ATR kinase is essential for DNA damage responses to replication stress. Loss of Drp1 induces replication stress and this is further increased by loss of ATR causing increased DNA damage and cell death. 
DETAILED DESCRIPTION OF THE INVENTION
For clarity and not by way of limitation, the detailed description is divided into the following subsections:
(i) inhibitors of Drp1;
(ii) formulations of Drp 1 inhibitors; (iii) agents for use with Drp 1 inhibitors; and (iv) methods of treatment.
Inhibitors of Drp1
In certain non-limiting embodiments, inhibitors of Drp1 that may be used according to the invention include Small molecule inhibitors such as the compounds disclosed in non-limiting embodiments, a Drp 1 inhibitor is mdivi-1 or a mdivi-1 related compound which exhibits at least 50% of the biological activity of mdivi-1 on mitochondrial morphology. In specific, non-limiting embodiments, a Drp1 inhibitor inhibits a Drp1 protein selected from the group consisting of isoform 1 (NCBI Ace. No. NP 036192.2 (SEQ ID NO: 1)), isoform 2 (NCBI Ace. No. NP 036193.2 (SEQ ID NO:2)), isoform 3 (NCBI Ace. No. NP 005681.2 (SEQ ID NO:3)) and protein as set forth in GenBank Accession No. AAH24590.1 (SEQ ID NO:4).
In certain non-limiting embodiments, inhibitors of Drp1 that may be used according to the invention include nucleic acids that inhibit expression and/or reduce activity of Drp1, for example but not limited to ribozymes, antisense oligo nucleotide inhibitors, and siRNA inhibitors. A "ribozyme' refers to a nucleic acid capable of cleaving a specific nucleic acid sequence. Within Some embodiments, a ribozyme should be understood to refer to RNA molecules that contain anti sense sequences for specific recognition, and an RNA-cleav ing enzymatic activity, see, for example, U.S. Pat. No. 6,770, 633. In contrast, "antisense oligonucleotides' generally are Small oligonucleotides complementary to a part of a gene to impact expression of that gene. Gene expression can be inhib ited through hybridization of an oligonucleotide to a specific gene or messenger RNA (mRNA) thereof. In some cases, a therapeutic strategy can be applied to dampen expression of one or several genes believed to initiate or to accelerate inflammation, see, for example, U.S. Pat. No. 6,822,087 and WO 2006/062716. A "small interfering RNA" or "short inter fering RNA" or "siRNA" or "short hairpin RNA" or "shRNA" are forms of RNA interference (RNAi). An inter fering RNA can be a double-stranded RNA or partially double-stranded RNA molecule that is complementary to a target nucleic acid sequence, for example, caspase 6 or caspase 9. Micro interfering RNAs (miRNA) also fall in this category. A double-stranded RNA molecule is formed by the complementary pairing between a first RNA portion and a second RNA portion within the molecule. The length of each portion generally is less than 30 nucleotides in length (e.g., 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, or 10 nucleotides) . In some embodiments, the length of each portion is 19 to 25 nucleotides in length. In some siRNA molecules, the complementary first and second por tions of the RNA molecule are the "stem" of a hairpin struc ture. The two portions can be joined by a linking sequence, which can form the "loop" in the hairpin structure. The link ing sequence can vary in length. In some embodiments, the linking sequence can be 5, 6, 7, 8, 9, 10, 11, 12 or 13 nucle otides in length. Linking sequences can be used to join the first and second portions, and are known in the art. The first and second portions are complementary but may not be com pletely symmetrical, as the hairpinstructure may contain 3' or 5' overhang nucleotides (e.g., a 1, 2, 3, 4, or 5 nucleotide overhang). The RNA molecules of the invention can be expressed from a vector or produced chemically or syntheti cally. In certain non-limiting embodiments, the ribozyme, siRNA, or antisense RNA inhibits expression of Drp1 and may comprise a portion which is complementary to a nucleic acid sequence as set forth in one or more of GenBank Acces sion No. BC024590.1; NCBI Reference Sequence NM 012062.3 (transcript variant 1), NM 012063.2 (tran script variant 2) or NM 005690.3 (transcript variant 3) (see SEQ ID NO:5, 6, 7 and 8, respectively). In one specific, non-limiting embodiment, an siRNA may comprise the sequence 5'-AACGCAGAGCAGCGGAAAGAG-3' (SEQ ID NO:9) (Sugioka et al., 2004). In certain non-limiting embodiments of the invention, the inhibitor of Drp 1 may be Dynasore (Macia et al., 2006) . Experiments to date have not demonstrated a synergistic effect between Dynasore and cisplatin.
Additional Drp1 inhibitors may be identified as com pounds that have comparable effects on Drp 1 activity as Drp1 siRNA and mdivi-1, for example, but not limited to, induction of G2/M cell cycle arrest and aneuploidy (see, for example, FIGS. 10A and B).
Formulations of Drp 1 Inhibitors
In certain non-limiting embodiments, the present invention provides for pharmaceutical formulations for therapeutic use of a Drp 1 inhibitor. Such formulations are compositions com prising a Drp1 inhibitor together with one or more of the following: sodium chloride, a pharmaceutical buffer, a car rier, and a solvent. Non-limiting examples of solvents include water, saline, water-miscible alcohols, dimethylsulfoxide, and mixtures thereof. Non-limiting examples of carriers include albumin and cyclodextrin.
In particular, non-limiting embodiments of the invention, the Drp 1 inhibitor is a compound disclosed in US2005/ 0038051 and/or US2008/0287.473 and is comprised in a phar maceutical composition further comprising human serum albumin and/or cyclodextrin 2-Hydroxypropyl-3-cyclodex trin (HP-3-CD). In a specific, non-limiting embodiment, the Drp1 inhibitor is mdivi-1 and is comprised in a pharmaceu tical composition further comprising albumin (e.g., human serum albumin ("HSA)) and/or cyclodextrin 2-Hydroxypro pyl-f-cyclodextrin (HP-8-CD).
In particular non-limiting embodiments, the molar ratio of Drp 1 inhibitor to HSA is between 0.01:1 to 1:1. In a specific non-limiting embodiment, the molar ratio of Drp 1 inhibitor to HSA is 1:2.25. In certain non-limiting embodiments, the concentration of HSA is between 0.01% to 30% (weight/ volume; w/v). In a subset of such embodiments, the Drp1 inhibitor is mdivi-1.
In particular non-limiting embodiments, the molar ratio of Drp 1 inhibitor to cyclodextrin (e.g., HP-3-CD) is between 0.01:1 and 1:1. In particular, non-limiting embodiments, the concentration of HP-B-CD is between 1% to 50% w/v. In a specific, non-limiting embodiment, the concentration of HP B-CD is between about 35-40% w/v. In a subset of such embodiments, the Drp 1 inhibitor is mdivi-1.
Agents for Use with Drp1 Inhibitors
One or more Drp 1 inhibitor may be used in conjunction with treatment with one or more other antiproliferative agent, sometimes referred to herein as a "second antiproliferative agent." Suitable antiproliferative agents include but are not limited to radiation therapy and chemotherapeutic agents. 
Methods of Treatment
The present invention relates to methods for reducing cell proliferation and/or promoting cell death by inhibiting Drp1.
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In certain non-limiting embodiments, the invention pro vides for a method for reducing cell proliferation and/or pro moting cell death by administering, to a cell, an effective amount of a Drp1 inhibitor, optionally in conjunction/com bination with administering an effective amount of a second antiproliferative agent. Examples of second antiproliferative agents are provided above. An effective amount' is an amount that reduces cell proliferation and/or promotes cell death. Where the Drp 1 inhibitor is used in conjunction/com bination with a second antiproliferative agent, the amount of each may in Some instances be less than an effective amount for that agent taken singly, but when both are used effective ness is achieved.
"In conjunction/combination with." "in conjunction with or "in combination with all mean that the Drp1 inhibitor and the second antiproliferative agent are administered to a cellor Subject as part of a treatment regimen or plan. These terms do not require that the Drp 1 inhibitor and second antiprolifera tive agent are physically combined prior to administration nor that they be administered over the same time frame. For example, drawing analogy to electronics, they may be admin istered in series or in parallel.
In certain non-limiting embodiments, the invention pro vides for a method for reducing cell proliferation and/or pro moting cell death in a subject in need of Such treatment comprising administering, to the Subject, an effective amount of a Drp 1 inhibitor, optionally in conjunction with a second antiproliferative agent.
In certain non-limiting embodiments, the present invention provides for a method of treating a disorder associated with cell proliferation comprising administering, to a subject in need of such treatment, an effective amount of a Drp 1 inhibi tor, optionally in conjunction with a second antiproliferative agent.
A Subject is a human or a non-human Subject, such as a primate, dog, cat, horse, cow, pig, sheep, goat, etc.
A "subject in need of such treatment" is a subject suffering from a disorder, or at risk of developing a disorder, where the disorder involves unwanted cell proliferation, including but not limited to neoplastic disorders, cancer (Solid and non Solid), and disorders of immunity.
In certain non-limiting embodiments, the invention pro vides for a method for reducing cancer cell proliferation and/or promoting cancer cell death in a Subject in need of such treatment comprising administering, to the Subject, an effec tive amount of a Drp 1 inhibitor, optionally in conjunction with a second antiproliferative agent.
In certain non-limiting embodiments, the present invention provides for a method of treating a cancer in a Subject com prising administering, to the Subject, an effective amount of a Drp1 inhibitor, optionally in conjunction with a second anti proliferative agent.
Cancers and cancer cells which may be treated according In certain non-limiting embodiments, a secondary antipro liferative agent, where used, is a administered by a route selected from the group consisting of intravenous, intramus cular, Subcutaneous, oral, intraarterial, intraperitoneal, intrathecal, intranasal, pulmonary, vaginal or rectal. In certain non-limiting embodiments, a secondantiproliferative agent is administered via an implant. In certain non-limiting embodi ments, a second antiproliferative agent is administered by local instillation, for example, at a tumor site or site of tumor resection.
In a specific non-limiting embodiment, the Drp1 inhibitor is mdivi-1, and is administered to achieve a local concentra tion at the site where cell proliferation is to be inhibited of between about 0.001 to 100 uM, or between about 0.1 to 50 uM.
In a specific non-limiting embodiment, the second antipro liferative agent is cisplatin, and is administered to achieve a local concentration at the site where cell proliferation is to be inhibited of between about 0.001 to 100 uM, or between about 0.1 to 50 uM.
In a specific non-limiting embodiment, the second antipro liferative agent is cisplatin, and is administered at a dose of 10-100 mg/m, administered intravenously.
In a specific non-limiting embodiment, the second antipro liferative agent is carboplatin, and is administered at a dose of 100-400 mg/m, administered intravenously.
In a specific, non-limiting embodiment, cisplatin or carbo platin is administered with HSA carrier at a molar ratio of cisplatin to HSA of about 1:2.25), MDA-MB-231 p" cell line was established by culturing MDA-MB-231 cells in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 1% penicillin streptomycin, 1 mM Sodium pyruvate, 50 ug/ml uridine, and 50 ng/ml ethidium bromide for at least four weeks (King and Attardi, 1996) . DNA transfection was performed using FuGENE 6 (Roche) and siRNA transfection was performed using oligofectamine (Invitrogen) according to the manufac tures instructions. Stable cell lines were established by G418 selection and cell sorting following transfection. Expression Vectors and RNA Interference. pAcGFP1-Mito and psRed2-Mito vectors were pur chased from Clontech. Histone H2B-GFP (Kanda et al., 1998) Cells were transfected with either control or Drp 1 siRNA and replated into 96-well plates at the following day. Cell proliferation was determined at 24 h intervals using a CyOUANT Direct Cell Proliferation Assay kit (Invitrogen), according to the manufacturers instruction.
Apoptosis Detection. Apoptosis was determined by staining cells with Annexin V-FITC and propidium iodide (PI) using an FITC Annexin V Apoptosis Detection Kit (BD PharMingen, San Diego, Calif.) followed by flow cytometric analysis using a CyAn ADP Analyzer (Beckman Coulter, Brea, Calif.). Data were ana lyzed using Summit Software.
Cell Synchronization. MDA-MB-231 cells were synchronized at G2/M phase by single thymidine (2 mM) block (19 h) followed by release into nocodazole (100 ng/ml)-containing media (16 h) (thymi dine/nocodazole block).
Cell Cycle Analysis. For DNA content analysis, cells were trypsinized and fixed in 70% ice-cold ethanol overnight at 4°C. After fixation, the cells were washed with 1% BSA/PBS, and permeabilized using 0.25% triton-X 100 in 1% BSA/PBS. Cells were then incubated in PI solution (PBS containing 50 g/ml of PI and 40 ug/ml of RNase A) for 30 min at room temperature. S phase cells were detected using abromodeoxyuridine (BrdU) incorporation assay. Cells were pulse-labeled with 10 LM BrdU for 30 min at 37° C. Cells were then trypsinized and fixed in 70% ice-cold ethanol overnight at 4°C. DNA was denatured in 2 NHCl containing 0.5% Triton X-100, and the cells were then neutralized with 0.1 MNaBO7. Cells were then stained with FITC-labeled anti-BrdU antibody (BDBio sciences, San Jose, Calif.). To determine the number of cells in mitosis, cells were fixed, permeabilized and stained with Alexa Fluor 647-conjugated phospho-Histone H3 (Ser 10) antibody (Cell signaling technology). Samples were then analyzed on a CyAn ADP Analyzer (Beckman Coulter, Brea, Calif.). 5x10" events per sample were acquired to ensure adequate mean fluorescence levels. Data were analyzed using Summit software.
ATP Measurement.
Total cellular ATP content was determined using a lumi nescent ATP detection kit, ATPlite (PerkinElmer Life Sci ences, Boston, Mass.), according to the manufacturers instructions. The luminescence intensity was measured using a microplate reader, Synergy 2 (BioTek instruments, Winooski, Vt.).
Extracellular Flux (XF) Analysis. Oxygen consumption rate (OCR) and extracellular acidi fication rate (ECAR) were measured as we previously described (Qian and Van Houten, 2010) . Cells were seeded in XF24 cell culture plates at 4x10" cells/well and incubated in 5% CO at 37° C. Prior to the analysis, cells were washed and growth medium was replaced with bicarbonate-free modified RPMI 1640 medium, the "assay medium' (Molecular Devices, Sunnyvale, Calif.). Cells were then incubated for another 60 min in a 37°C. incubator without CO. OCR and ECAR measurements were then performed simultaneously using a Seahorse XF24 Extracellular Flux Analyzer (Sea horse Bioscience, North Billerica, Mass.). To measure mitochondrial membrane potential and Super oxide generation, cells were incubated in either 20 nM of TMRM (Invitrogen) or 2.5uMofMitoSox (Invitrogen) for 20 min at 37°C., respectively. Cells were then trypsinized and suspended in HBSS containing 1% BSA. TMRM and Mito Sox fluorescence intensity were analyzed using a CyAn ADP Analyzer (Beckman Coulter, Brea, Calif.). 5x10" events per sample were acquired and the results were analyzed using Summit software.
Western Blot Analysis. Cells were lysed in cell lysis buffer (Cell signaling tech nology) containing complete protease inhibitor (Roche). Cell lysates were cleared at 15,000 rpm for 15 min at 4°C. The protein content of the cleared cell lysate was quantified using a Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Her cules, Calif.). Then the cell lysates were combined with 2xSDS sample buffer. The equal amount of protein was sepa rated on Tris-glycine or Tris-acetate gels (Invitrogen). The separated proteins were blotted onto a polyvinylidene difluo ride membrane and blocked overnight at 4°C. in phosphate buffered saline containing 0.1% Tween 20 and 10% nonfat dry milk (blocking buffer). Membranes were incubated with primary antibody in blocking buffer overnight at 4° C. Pri mary antibodies used were: Drp 1 and Opal were from BD Biosciences, B-actin (AC-15) and ATM (MAT3-4G10/8) were from Sigma, cyclin E (HE12), cyclin B1 (H-20) and ATR (N-19) were from Santa Cruz, Biotechnology, phospho cdc2 (Tyr15), Chk1 (2G1 D5), phospho-Chk2 (Thr68) (C13C1), Chk2 (1C12) and cleaved caspase-3 were from Cell Signaling Technology, phospho-Chk1 (Ser317) was from R&D systems, cdh1 was a gift from Dr. Yong Wan, phospho ATM (S1981) was from Epitomics, and phospho-Histone H2AX (Ser139) (JBW301) was from Millipore. Membranes were then washed and incubated in peroxidase conjugated anti-rabbit IgG (Sigma), anti-mouse IgG (Sigma), or anti goat IgG (Santa Cruz, Biotechnology) secondary antibody for 1 hat room temperature. Membranes were washed and devel oped using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).
Immunofluorescence.
Cells were fixed in 4% paraformaldehyde (Electron microscopy sciences, Hatfield, Pa.) in PBS for 15 min at 37° C. and blocked using 3% BSA in PBS containing 0.3% Triton X-100 overnight at 4°C. For centrosome staining, cells were incubated for 1 hour at room temperature with anti-y-tubulin antibody (Sigma), followed by an incubation with the sec ondary Alex Fluor 594 goat anti-mouse antibody (Invitrogen) for 1 hour at room temperature. B-tubulin was visualized by incubation with Alex Fluor 555-conjugated anti-f-tubulin antibody (Cell Signaling Technology). Slides were mounted with VECTASHIELD mounting medium containing DAPI (Vector Laboratories, Burlingame, Calif.). Confocal images were captured using a laser-scanning confocal microscope, Olympus FLUOVIEW FV-1000, with a PlanApo N 60x oil immersion objective, NA=1.42 (Olympus).
Live Cell Confocal Microscopy Analysis. Cells were plated on 40 mm diameter coverglass and incu bated for 24 hours at 37° C. The coverglass was then assembled into an environmentally controlled closed cham ber system, FCS2 live cell chamber (Bioptechs, Butler, Pa.). The chamber system was then mounted on an inverted con focal microscope (Nikon A1, Nikon), controlled by NIS Elements software. Leibovitz's L-15 medium supplemented with 10% FBS and 1% penicillin-streptomycin was used, and the temperature of the chamber was maintained at 37° C. 13 during the imaging. The excitation wavelengths for GFP and DsRed2 were 488 and 543 nm, respectively. Signal was col lected through a Plan Apo VC 60x Oil immersion objective, NA=1.40 (Nikon). The number of individual Z-stacks was set to cover the entire thickness of the cell, with the step size of 1 um. Time-lapse images were captured at the interval of no time delay. The perfect focus system (PFS) was applied to automatically correct possible focus drift during the period of time-lapse imaging. Post-acquisition analysis of image files was performed using MetaMorph (Molecular Devices), Image J (National Institutes of Health) and Photoshop (Adobe).
Statistical Analysis. Data are expressed as meanistandard deviation. A Stu dent's t test was used for the comparisons between two groups. p(0.05 was considered statistically significant.
Results
Loss of the fission protein Drpl causes mitochondrial hyperfusion and induces G2/M cell cycle arrest and aneup loidy. To investigate the functional consequences of defective mitochondrial dynamics on cell cycle progression, we knocked down the expression of the mitochondrial fission protein Drp1 using siRNA. Cell cycle analysis revealed that loss of Drp1 induced G2/M cell cycle arrest and aneuploidy (DNA content>4N) in a variety of cell lines independent of their p53 status (FIG. 1A: FIG. 8A) . Since MDA-MB-231 cells showed the most severe phenotype, we selected this cell line for further investigations into the underlying mechanism.
Mitochondria in MDA-MB-231 cells are thinner and have less cristaethan mitochondria in MCF7 cells (FIG.1E) . Drp1 deficiency in MDA-MB-231 cells induced a hyperfused mito chondrial network as expected (FIG.1B) , as well as a remark able decrease in cell proliferation (FIG. 1C) . To confirm that these phenotypes were the consequences of Drp1 deficiency and to exclude the possible off-target effects of the siRNA, we employed a selective small molecule inhibitor of Drp1, mdivi-1 (Cassidy-Stone et al., 2008). Mdivi-1 induced the similar G2/M cell cycle arrest and aneuploidy as Drp 1 defi ciency achieved by using siRNA (FIG. 8B) . Thus, Drp 1 func tion is essential for proper cell cycle progression.
To determine whether mitochondrial fission per se is directly responsible for the G2/M cell cycle arrest and aneu ploidy observed in Drpl-deficient cells, we knocked down an essential mitochondrial fusion protein Opal (Cipolat et al., 2004) to counteract the Drp 1 knockdown-induced mitochon drial hyperfusion. Knockdown of Opal restored the mito chondrial fragmentation in Drp1-deficient cells (FIG. 1D) . These Drp 1 and Opal double knockdown cells showed lower G2/M accumulation and a two-fold decrease in aneuploidy as compared to when Drp 1 alone was knocked down (compare FIGS. 1D and 1A) . These results indicate that the G2/M cell cycle arrest and aneuploidy induced in Drp1-deficient cells required mitochondrial hyperfusion.
The G2/M cell cycle arrest and aneuploidy observed in Drpl-deficient cells are not caused by changes in mitochon drial energy metabolism. Cellular energy status has been recognized as important for cell cycle progression (Mandalet al., 2005) . Wetherefore evaluated if the mitochondrial energy metabolism plays a role in regulating the G2/M cell cycle arrest and aneuploidy in Drp1-deficient MDA-MB-231 cells. Contrary to the previous report using HeLa cells (Parone et al., 2008) , there is no depletion of total cellular ATP following Drp1 knockdown (FIG. 2A) . Since changes in total intracel lular ATP levels may not reflect the changes in mitochondrial metabolism in cancer cells because of the Warburg effect (Warburg et al., 1927) , we undertook a detailed analysis to address whether mitochondrial function is altered in Drp 1deficient cells. We observed a slight decrease in mitochon drial membrane potential (FIG. 2B) and about a ~25% decrease in the oxygen consumption rate (OCR) (FIG. 2C) , which is accompanied with a concomitant increase in extra cellular acidification rate (ECAR) (FIG. 2D) , a marker of glycolysis, in Drp1-deficient cells. Consistent with these data, we observed a decreased mitochondrial contribution (indicated by lower ATP levels in the presence of 2-deoxy glucose (2DG)) (FIG. 2E) , which is compensated by an increased glycolysis contribution (indicated by higher ATP levels in the presence of oligomycin) (FIG. 2F) , in order to maintain total cellular ATP levels in Drp1-deficient cells. These observations indicate that loss of Drp 1 in MDA-MB 231 cells reduces mitochondrial energy metabolism. ROS production due to mitochondrial dysfunction is frequently considered a cause of cellular damage and cell cycle arrest (Owusu-Ansah et al., 2008) . However, we observed no increase in mitochondrial ROS generation in Drp1-deficient MDA-MB-231 cells using the mitochondrial superoxide indicator MitoSox (FIG. 2G) . These results indicate that the G2/M cell cycle arrest and aneuploidy observed in Drp 1deficient cells cannot be attributed to changes in total ATP production or mitochondrially generated ROS.
To further exclude the potential role for mitochondrial energy and ROS in mediating the cell cycle defects observed in Drpl-deficient cells, we examined cell cycle progression in MDA-MB-231 p0 cells following knockdown of Drpl. Mito chondria in p0 cells do not contribute to total cellular ATP generation and are unable to produce ROS (Weinberg et al., 2010) , due to a deficiency in mitochondrial oxidative phos phorylation that is caused by the depletion of mitochondrial DNA (Qian and Van Houten, 2010) (FIG. 2H) . Loss of Drp1 in MDA-MB-231 p0 cells resulted in elongated mitochondria (FIG. 2I) , G2/M cell cycle arrest and aneuploidy (FIG. 2J) , that are similar to what we observed in the parental MDA MB-231 cells (FIG. 1A, B ). Furthermore, treatment of MDA MB-231 cells with either oligomycin, a complex V inhibitor that Suppresses mitochondrial respiration, FCCP, an uncou pler that depolarizes mitochondrial membrane potential, or antimycin A, a complex III inhibitor that stimulates mito chondrial ROS production, did not induce G2/M cell cycle arrest and aneuploidy (FIG. 2K) . These data further support our conclusion that the G2/M cell cycle arrestandaneuploidy observed in Drp1-deficient cells are not caused by defects in mitochondrial energy metabolism.
The G2/M cell cycle arrest observed in Drp1-deficient cells is not caused by disruptions in the molecular machinery that is essential for the G2/M cell cycle transition. To investigate the mechanisms underlying the G2/M cell cycle arrest and aneuploidy observed in Drp1-deficient cells, we synchro nized MDA-MB-231 cells at G2/M phase using a single thy midine block followed by nocodazole treatment (henceforth referred to as a thymidine/nocodazole block), and then moni tored the changes in G2/M phase-related molecular events following the release from G2/M cell cycle block (FIG. 3A) . Both control and Drp1-deficient MDA-MB-231 cells were able to be blocked at G2/M phase as shown by their 4N DNA content immediately following the thymidine/nocodazole block (FIG. 3B 0h release) . Phosphorylation of histone H3 at serine residue (Ser10) is associated with chromosome con densation and mitotic entry (Crosio et al., 2002) , therefore, the phosphorylation of historic H3 is used as a marker to distinguish M phase cells from G2 phase cells, both of which contain 4N DNA content. Immediately following the thymi dine/nocodazole block we observed that the levels of positive phospho-histone H3 in Drp 1 knockdown cells was ~10-fold lower than in control cells (FIG. 3C) , even though both con trol and Drp1-deficient cells contained 4N DNA content. These data suggest that the accumulation of 4N DNA content in Drp1-deficient cells was largely due to the cell cycle arrest at G2 phase rather than M phase. Following the release from the G2/M block control cells rapidly entered the cell cycle such that the majority of cells were in G1 phase with 2N DNA content at 6 h (FIG. 3B) . In contrast, the majority of Drp 1deficient cells were still at G2/M phase as indicated by the large fraction of cells with 4N DNA content at 6h following release from the block (FIG. 3B) . These data indicated that loss of Drp1 prevented G2 to M cell cycle transition.
To examine the integrity of molecular events associated with M phase entry, we examined the activity of maturation/ mitosis-promoting factor (MPF). MPF is a heterodimeric protein composed of cyclin B and cdc2 serine/threonine kinase (Doree and Hunt, 2002) . Both the accumulation of cyclin B1 and dephosphorylation of cdc2 at Tyr15 are required for the initiation of mitosis (Norbury et al., 1991) . Drp1-deficient MDA-MB-231 cells were defective in the accumulation of cyclin B1 and the dephosphorylation of cdc2 at Tyr15 in response to thymidine/nocodazole block (FIG.  3D) . High levels of phosphorylated cac2 have previously been associated with effective G2/M cell cycle checkpoint activation (Lew and Kornbluth, 1996) . These data indicate that Drp 1 deficiency causes suppression of MPF activity and subsequent defect in mitotic entry. Cdh1 is required for the degradation of cyclin B1 and the expression pattern of cdh1 through the cell cycle is similar to that of cyclin B1 (Listovsky et al., 2004) . Immediately following the release from the thymidine/nocodazole block control cells showed high levels of cyclin B1 and cdh1, which rapidly declined during the next few hours. This is in stark contrast to the Drp1 knockdown cells, which showed initially low levels of cyclin B1 and very low levels of cdh1 with high levels of phosphorylated cdc2. These Drp1 knockdown cells once released from the thymi dine/nocodazole block showed a slow increase in cyclin B1 and cdh1, with a decrease in phosphorylated cdc2 (FIG. 3D) . This particular pattern observed in Drp1 knockdown cells represents the slow progression through G2/M phase, which is associated with Subsequent aneuploidy. These data are consistent with an induction of a G2/M cell cycle checkpoint in Drp1-deficient cells rather than a disruption in the molecu lar machinery that is essential for the G2/M cell cycle transi tion.
Loss of Drp1 induces chromosomal instability and cen troSome overamplification. Aneuploidy is frequently a con sequence of the chromosomal instability that is associated with defects in mitotic segregation of chromosomes (Rajago palan and Lengauer, 2004) . We observed misaligned chromo Somes in metaphase, and lagging chromosomes in anaphase as Drp1-deficient cells progressed through mitosis (FIG. 4A,  B) . The hyperfused mitochondrial network was maintained throughout the mitosis in Drpl-deficient cells, in contrast to the fragmented mitochondrial morphology observed in con trol cells (FIG. 4A) . These data indicate that defects in mito chondrial fission lead to the defects in chromosome segrega tion during mitosis. Given that Drp1-deficient cells still retained the ability to progress through mitosis (albeit at a greatly reduced rate) (FIG. 3D) , such defects in chromosome segregation could give rise to aneuploidy.
Abnormal extra centrosomes are known to be associated with chromosome instability via formation of aberrant mitotic spindles (Ganem et al., 2009) . Depending on the cell cycle phase, normal cells contain one or two centrosomes. We observed that Drp1-deficient cells frequently contained more than two centrosomes relative to control cells (FIGS. 4C, D and E). The Drpl-deficient cells containing extra cen troSomes also showed abnormal nuclear morphology and micronuclei (FIG. 4C) , a phenotype that is again indicative of chromosome instability. In images obtained from single focal plane we observed that over-amplified centrosomes were often Surrounded by aggregated mitochondria, indicating that mitochondrial aggregation is associated with centrosomal abnormalities (FIG. 4D) .
Loss of Drp1 induces mitochondrial aggregation around the microtubule organizing center (MTOC). Since the changes in the mitochondrial morphology perse play a direct role in mediating Drp 1 deficiency-induced cell cycle defects, as demonstrated by that knockdown of mitochondrial fusion protein Opal reversed the G2/M arrest and aneuploidy observed in Drp1-deficient cells, we undertook a detailed analysis of mitochondrial dynamics in Drpl-deficient cells. Microtubules originate at the centroSome (the main microtu bule organizing center), and are tracks for mitochondrial transportation and distribution. Since we had observed a cen trosome defect in Drp1-deficient cells, we reasoned that the morphological relationship between mitochondria and microtubules might be defective in these cells. In control MDA-MB-231 cells, both the mitochondria and microtubules were observed to be widespread in the cytoplasm, and the area that contained a high concentration of microtubules indirectly marked the location of the MTOC (FIG. 5A, B) . In Drp1 deficient cells we observed that mitochondria aggregated around the MTOC, with few elongated mitochondria radiat ing along microtubule tracks from the mitochondrial aggre gates toward the peripheral regions of the cells. We propose that this morphological remodeling results from the retraction and fusion of mitochondria dispersed in peripheral region of the cytoplasm to the MTOC, and this in turn lead to mito chondrial aggregation and a large region of cytoplasm that contains no mitochondria (for example see "cell b" in FIG.  5B) . It is also notable that "cell b" shows an abnormal nuclear morphology, and the micronuclei were located inside Such mitochondrial aggregates. Therefore the aggregation of mito chondria around the MTOC may affect intracellular homeo Stasis such as Ca2+ signaling that directly contributes to the defects of centrosome duplication and other cell cycle related events (Matsumoto and Mailer, 2002) .
Mitochondrial aggregates have been described as clusters of tubules rather than a large mass of coalescing membrane (Smirnova et al., 1998) . However, the exact process through which the highly interconnected mitochondrial aggregates are formed is not known. We generated time-lapse movies that revealed markedly reduced mitochondrial motility and redistribution due to lack of fission in Drp1-deficient cells (FIG.5C and supplementary material Movie 1-4) . Neverthe less, mitochondria were still able to undergo some remodel ing in these cells, even with the limited frequency and within the limited spatial region. For example, a branching event in Drp1-deficient cells is indicated "a" in FIG. 5D and supple mentary material Movie 5. Furthermore, fusion is not limited to end-joining fusion between separate mitochondria, and can occur as a cross-fusion between branched mitochondrial tubules that make contact as shown in region "b' in FIG. 5D and Supplementary material Movie 6. In this example, mito chondria underwent a morphological change from a simple fork shape to a complicated net-like structure. These pre served branching and fusion abilities in Drp1-deficient cells eventually build up a complicated mitochondrial network, which appears as mitochondrial aggregates. We believe that these examples are the paradigms that demonstrate how a vast hyperfused mitochondrial network may be generated in the condition of lack of fission. The G2/M cell cycle arrest and aneuploidy observed in Drpl-deficient cells are consequences of replication stress initiated DNA damage signaling that involves ATM/Chk2 and ATR/Chk1 kinases. We sought to understand the molecular mechanism that causes the G2/M arrest and aneuploidy in Drp1-deficient cells. Mitochondrial hyperfusion induced either by overexpression of mutant Drp 1 (K38A) or by Drp1 inhibitor mdivi-1 has previously been associated with the onset of DNA replication and cyclin E accumulation in HCT116 and NRK cells (Mitra et al., 2009) . In contrast, we observed a decrease in cyclin E levels in Drpl-deficient MDA-MB-231 cells relative to control cells (FIG. 6A lanes  1 and 2) . Cyclin Elevels accumulate at the G1/S phase bound ary, decline during S phase and become low or undetectable when replication is complete (Ekholm et al., 2001) . To deter mine whether this reduction in cyclin E was a reflection of the accumulation of Drp1-deficient cells at G2/M phase, we used nocodazole to arrest both Drp1-deficient and control cells at the G2/M phase. While cyclin E was low in control cells arrested at G2/M with nocodazole, the cyclin E levels were not changed in nocodazole-treated Drp1-deficient cells (FIG.  6A-lanes 3 and 4) . Thus, cyclin E is maintained at high levels in G2/M phase in Drp1-deficient cells as compared to that in control cells. These results suggest that the control of cyclin E expression is uncoupled from the cell cycle in Drp 1deficient cells. Overexpression of cyclin E can induce G2/M cell cycle arrest, aneuploidy and genomic instability (Bart kova et al., 2005; Kecket al., 2007 : Spruck et al., 1999 . To determine whether cyclin E is required for the G2/M cell cycle arrest and aneuploidy observed in Drpl-deficient MDA-MB-231 cells, we disrupted cyclin E using siRNA (FIG. 6B) . The concurrent knockdown of cyclin E and Drp1 did not induce a G2/M cell cycle arrest and aneuploidy as compared when Drp1 alone was disrupted (FIG. 6C) , Sug gesting that the cell cycle defects observed in Drpl-deficient cells are cyclin E-dependent.
Dysregulated cyclin E expression and decreased cyclin B/cdc2 kinase activity have been previously associated with DNA damage response and G2/M cell cycle checkpoint acti vation (Bartkova et al., 2005: Kastan and Bartek, 2004) . We therefore examined the activities of ATM, Chk1 and Chk2, three kinases that are integral to the DNA damage response and activation of cell cycle checkpoint. In control and Drp1 deficient MDA-MB-231 cells, we observed that the activities of ATM, Chk1 and Chk2 kinases as indicated by the levels of their phosphorylation were increased in Drp1-deficient cells compared to control cells (FIG. 6D) . ATM phosphorylates Chk2 and activates G2/M cell cycle checkpoint through inhibiting cdc2kinase activity. We observed that ATM knock down impeded the phosphorylation of Chk2 and abrogated the G2/M cell cycle arrest and aneuploidy in Drp1-deficient cells (FIG. 6D, E ), suggesting ATM/Chk2-mediated signal ing is required for the cell cycle defects in cells that lack mitochondrial fission. ATR kinase-dependent phosphorylation and activation of Chk1 are central to the signal transduction axis activated by replication stress (Toledo et al., 2008) . The phosphorylation of Chk1 as well as the aberrant expression of cyclin E at G2 phase observed in Drpl-deficient cells suggested that repli cation stress is induced by the mitochondrial hyperfusion. ATR is essential for the stability of stalled DNA replication forks (Toledo et al., 2008) . As such, ATR disruption induces replication stress (Murga et al., 2009 ) and causes DNA double-strand breaks (DSBs) to be generated at sites of 18 stalled replication forks. We observed increased Chk2 phos phorylation and G2/M cell cycle arrest in ATR-deficient MDA-MB-231 cells, and as such ATR deficiency pheno copies Drp 1 deficiency in this replication stress-mediated cell cycle arrest (FIG. 6D, E) . In order to test the hypothesis that ATR deficiency would further increase the replication stress in Drp1-deficient cells we knocked down both proteins in MDA-MB-231 cells. Significantly, the knockdown of both Drp1 and ATR dramatically increased the levels of Y-H2AX (a marker of DNA damage), the cleavage of caspase-3 and the number of Annexin V-positive cells that both are associated with apoptosis (FIG. 6D, F) . Thus, ATR is essential in pre venting the replication stress-associated DNA damage and hence the survival of Drp1-deficient cells.
Discussion
The replication stress-mediated genome instability and cell cycle defects identified in this study revealed a novel mecha nism underlying Drp1 deficiency-related cellular dysfunc tion. These cell cycle defects were not a result of loss of mitochondrial oxidative phosphorylation and ATP produc tion, but required the hyperfused state of mitochondrial mor phology, as Opal knockdown was able to abrogate these effects. Thus, we have separated a function for Drp1 in genome stability from its potential role in mitochondrial energy metabolism. We have identified that dysregulation of cyclin E expression in G2 phase is a direct consequence of Drp1 deficiency causing replication stress and a Subsequent DNA damage response that is associated with activation of ATM kinase-dependent delay of mitotic entry. Preventing ATR-mediated DNA repair signaling in response to replica tion stress in Drp1-deficient cells enhances DNA damage and cell death (FIG.7) . Together these data indicate that the cycles of mitochondrial fission and fusion are integrated with the cell cycle apparatus that are essential for genome stability.
Mitochondria form a highly interconnected network at the G1/S border, and the disassembly of this hyperfused network occurs when the GUS transition process is completed (Mitra et al., 2009) . This phenomenon Suggests that mitochondrial fission, which is responsible for the disassembly of the hyper fused mitochondrial network, may play a significant role for the progression of following stages of the cell cycle after G1/S transition. In support of this idea, our data revealed that persistent mitochondrial hyperfusion due to loss of fission protein Drp1 is associated with aberrant accumulation of cyclin E in G2 phase when mitochondrial network was not able to be dissembled in this phase following G1/S transition. Cyclin E promotes cell cycle entry into S phase and is related with DNA replication associated functions (Ekholm and Reed, 2000) . Cyclin E overexpression impacts DNA replica tion and leads to replication stress (Toledo et al., 2011) . We observed a reduced rate of DNA replication (shown by the decrease of BrdU-positive S-phase cell) in Drp1-deficient cells (supplementary material FIG. S1A) , which may reflect either a reduced rate of replication or the activation of a G1/S or intra-S phase cell cycle checkpoint. These data are consis tent with previous reports that described a similar reduction in BrdU incorporation (Mitra et al., 2009; Parone et al., 2008) . However, the underlying mechanism is not dependent on the depletion of mitochondrial energy as Suggested in these reports that activates metabolic checkpoint, as we were not able to phenocopy Drp 1 deficiency-induced cell cycle defects by pharmacological inhibition of mitochondrial energy metabolism (FIG. 2K) . Rather, the reduction in the number of BrdU-positive S-phase cells in Drp1-deficient cells reflects replication stress that might be caused by either the accumu lation of stalled replication forks, inefficient firing of replica tion origin (Liberal et al., 2011) and/or defects in pre-repli cation complex (preRC) assembly (Ekholm-Reed et al., 2004) , phenotypes that have all been associated with cyclin E overexpression. Such cyclin E-mediated replication stress induces DNA damage and triggers the cell cycle checkpoint in G2 phase (Bartkova et al., 2005) . Further, the accumulation of cyclin E is able to induce centrosome overduplication and chromosome instability (Nakayama et al., 2000; Spruck et al., 1999) . Our results showing an increased number of centroSomes and chromosome instabil ity in Drp1-deficient cells are consistent with these reports (FIG. 4) . However, the mechanism underlying Drp1 defi ciency-mediated alterations in mitochondrial dynamics and cyclin E dysregulation is unknown.
Our results revealed that as a consequence of replication stress in Drp1-deficient cells, ATR/Chk1 and ATM/Chk2 DNA damage signaling cascades are activated (FIG. 6D) . A major cellular defense against DNA damage and control of cell cycle transition and cell death is a signaling network known as the DNA damage response (DDR) that is largely regulated by the ataxia telangiectasia mutated (ATM) and . Cyclin E dysregulation-in duced abnormalities in DNA replication are known inducers of the ATR/Chk1 cascade (Kastan and Bartek, 2004) . ATR kinase activity is increased by single-stranded DNA (SS DNA). ssDNA accumulates at stalled replication forks that may arise as a consequence of replication stress (Cimprich and Cortez, 2008) . Persistent replication stress can lead to the generation of DNA DSBs when stalled replication forks are subject to nucleolytic attack. ATM kinase activity is then increased by DNADSBs and the subsequent G2/M cell cycle checkpoint is induced. It is noteworthy that knockdown of ATM prevented both G2/M arrest and aneuploidy in Drp1 deficient cells (FIG. 6E) , indicating that these cell cycle defects are dependent on ATM-mediated DNA damage sig naling. ATM and ATR share many of the numerous substrates that promote cell cycle arrest and DNA repair. However, one of the best established roles of ATR that is not shared by ATM is preventing the collapse of stalled replication forks in gen erating DSBs (Cimprich and Cortez, 2008) . Thus, ATR should attenuate DSBs and subsequent ATM kinase activity under conditions that induce replication stress. Our results showed that ATR kinase inhibition by knockdown of ATR in Drp1-deficient cells enhanced phosphorylation of H2AX and apoptosis. This increase in DNA damage and cell death is considered as the consequence of Drp1 deficiency-related replication stress under the condition of in the absence of ATR. This finding is reminiscent of the increased DNA dam age and cell death when cells overexpressing cyclin E were treated with an ATR kinase inhibitor (Toledo et al., 2011) . Since ATR activity is restricted to S and G2 phase (Toledo et al., 2011) , these data further Suggest that the direct impact of Drp1 disruption occurs in these phases. Moreover, cen trosome overduplication requires functional G2/M check point (Inanc et al., 2010) , and ATM is also involved in initi ating the signaling that regulates centroSome reduplication upon DNA damage (Fukasawa, 2007) .
Mitochondrial fission is required for inheritance and par titioning of mitochondria during cell division (Westermann, 2010) . Inhibiting Drp1-mediated mitochondrial fission has been reported to cause accumulation of mutant mtDNA (Malena et al., 2009) . Our results provided the first evidence that mitochondrial dynamics are involved in initiating mito chondria-to-nucleus retrograde signaling, in order to ensure proper mitochondrial inheritance by enforcing cell cycle delay upon detection of abnormal mitochondrial morphol ogy. One of the important roles of mitochondrial hyperfusion at G1/S border is postulated to allow homogenization of mitochondrial matrix and mtDNA. After G1/S transition is completed, mitochondrial fission has to take place during S G2 and M phase to ensure daughter cells inherit even and healthy mitochondria. When mitochondrial fission is impaired, the activation of G2/M cell cycle checkpoint thus allows more time for cells to fragment their mitochondria in preventing unequal segregation of mitochondria and mtDNA.
From abroader perspective, the genomic instability that we have identified in this study as a result of Drp 1 deficiency may help explain why disruption of Drp 1 induces lethality (Ishi hara et al., 2009; Labrousse et al., 1999; Waterham et al., 2007) and cellular senescence (Yoon et al., 2006) . Since replication stress has been observed in human precancerous lesions (Gorgoulis et al., 2005) , alterations in mitochondrial dynamics may also play a significant role in cancer etiology. Finally, our data Support a novel anti-cancer strategy wherein concurrent targeting of the mitochondrial dynamics protein and the DNA repair machinery involved in the repair of rep lication stress-induced DNA damage might provide more efficient cancer cell killing.
EXAMPLE

Anti-Tumor Activity of Mdivi-1, Alone and in Combination with Cisplatin
The effect of Drp 1 inhibition on the cell cycle was tested. Cells were transfected with control or Drp1 siRNA for 72 and 96 hours, and then were stained with P1 and their DNA contents measured by flow cytometry. The percentage of cells in G2/M stage and the percentage of cells containing DNA content>4N (which indicates aneuploidy) were quantified. Analogous studies were performed using, instead of siRNA, the Drp 1 inhibitor, mdivi-1, at a concentration of 50M for 24 and 48 hours. The results of siRNA and mdivi-1 inhibition, respectively, are shown in FIGS. 10A and 10B, which show that inhibition of Drp1 by these agents induces G2/M cell cycle arrest and aneuploidy.
The effect of Drp1 inhibition of chromosome stability was then evaluated. MDA-MB-231 cells that have been engi neered to stably express a mitochondrial marker protein pAcGFP-1-mito were treated with mdivi-1 for 7 hours. Mitotic cells were selected for examining the morphology of their chromosomes and mitotic spindles. Chromosomes were visualized by DAPI, and mitotic spindles were visualized by staining cells with Alex-Fluor 555-conjugated anti-fi tubulin antibody. The results are shown in FIG. 11; To test the effect of Drp-1 inhibition on the effectiveness of cisplatin, in a first series of experiments, MDA-MB-231 cells were transfected with control or Drp 1 siRNA, and 48 hours later were then treated with 40 uM of cisplatin for a 24 hour period. The effect of different concentrations of cisplatin on the Drp1 knockdown cells is shown in FIG. 13A, where the SubG1 portion in the cell cycle profile indicates cytotoxicity. In a second series of experiments, a LIVE/DEAD Viability/ Cytotoxicity kit (Invitrogen) was used to evaluate the effect of inhibition of Drp 1 by mdivi-1 on cisplatin cytotoxicity. In this test, the percentage of lice and dead cells are determined simultaneously with two probes, calcein AM and ethidium homodimer (Eth)-1). The nonfluorescent cell-permeant cal cein AM is converted to the intensely green fluorescent cal cein by ubiquitous intracellular esterase only present in live cells. EthD-1 is excluded by the intact plasma membrane of live cells but is able to enter cells with damaged membranes and undergo a 40-foldenhancement of red fluorescence upon binding to nucleic acids. MDA-MB-231 cells were treated with various concentrations of cisplatin in the presence of DMSO or 50 mdivi-1 for 12 hours. Cells were then trypsinized and suspended in HBSS containing 1% BSA. Calcein AM and Ethl)-1 were added to the cell suspension at final concentrations of 0.1 uM and 8 uM, respectively, Fluo rescence intensity was analyzed on a CyAn ADP Analyzer (Beckman Coulter, Brea, Calif.) and the results were ana lyzed using Summit software. The live-cell population that was positively stained with calcein was detected in the bottom right region and indicated with an arrow. The dead cell popu lation that is positively stained with EthD-1 was detected in To explore this effect further, MDA-MB-231 cells were treated with DMSO as a vehicle control, 50 LM of cisplatin, 50 uM of mdivi-1, or 50 uM of cisplatin plus 50 uM of mdivi-1 for 2 hours. The cells were then washed with growth media and plated in black 96-well plates. Survivals were measured by CyOUANT assay. Data represent meant-SD. n=4 wells. The results, as shown in FIG. 14, show that short time exposure (2h) to mdivi-1 in combination with cisplatin had a synergistic effect in decreasing the survival of MDA MB-231 breast cancer cells. The action of mdivi-1 alone in such exposure condition was found to be reversible.
To evaluate whether the synergistic effects of Drp 1 inhibi tion and cisplatin could be extended to other types of cancer cells, breast cancer cells MDA-MB-231, non-small cell lung carcinoma cells H1299, and glioblastoma cells LN428 were treated with various combinations of cisplatin and mdivi-1 at indicated concentrations. After continuous exposure for 20 hours, cell death was determined by measuring the activity of caspase 3/7. The luminescence value that indicates the activ ity of caspase 3/7 for each combination was plotted on a 3D bar chart using SigmaPlot. As shown in FIG. 15A-C, syner gistic cell killing was observed between mdivi-1 and cisplatin in various types of cancer cells. Single compound exposure was found to have minimal effect in inducing cell death in these cells.
EXAMPLE
Mdivi-1 Solubility is Enhanced by Carrier Compounds
Experiments were performed to test the effect of the carrier compounds HSA and cyclodextrin on the solubility of mdivi 1 In a first set of experiments, Mdivi-1 dissolved in DMSO was used as stock solution. HSA-bound mdivi-1 was pre pared by diluting 50 mM stocks in DMSO with 15% HSA in 0.85% sodium chloride (Sigma) such that the final concen tration of mdivi-1 is 1 mM and the final molar ratio of mdivi-1 to HSA is 1:2.25. HSA-bound cisplatin was prepared by combining equal volume of 2 mM cisplatin in 0.85% sodium chloride with 30% HSA in 0.85% sodium chloride (molar ratio of cisplatin to HSA is 1:2.25), and followed by incuba tion in the dark at 37 degree for overnight (16-20 h) . MDA MB-231 cells were treated with HSA-bound mdivi-1 and/or HSA-bound cisplatin continuously for 48 h, and cell death was determined by western blot using antibody against acti vated caspase-3.
The results of these experiments indicate that human serum albumin can be used as an effective vehicle to improve the solubility of mdivi-1 for intravenous injection purpose, and also enhances the tumor specificity of mdivi-1. As shown in FIG. 16 , human serum albumin (HSA)-bound mdivi-1 enhanced the toxicity of HSA-bound cisplatin. Enhanced solubility of mdivi-1 by HSA is possibly mediated through the hydrophobic binding activity of HSA. HSA is also taken up by tumor cells at increased levels in comparison to normal cells, therefore, binding of mdivi-1 with HSA is expected to enhance the tumor-specific targeting. In addition, albumin is a major serum protein that cisplatin binds after intravenous infusion, however albumin-bound cisplatin is not as effective as free cisplatin. We have found that HSA-bound mdivi-1 is not only able to enhance the activity of free cisplatin, it also enhances the activity of HSA-bound cisplatin.
In 2. The method of claim 1, further comprising administer ing, to the cell, an effective amount of a second antiprolifera tive agent.
3. The method of claim 2 where the second antiprolifera tive agent is a platinum compound.
4. The method of claim 3 where the platinum compound is cisplatin.
5. The method of claim 3 where the platinum compound is carboplatin.
6. The method of claim 4 where the cisplatin is bound to albumin carrier. 9. The method of claim 7, further comprising administer ing, to the cell, an effective amount of a second antiprolifera tive agent.
A method
10. The method of claim 9 where the second antiprolifera tive agent is a platinum compound.
11. The method of claim 10 where the platinum compound is cisplatin.
12. The method of claim 11 where the cisplatin is bound to albumin carrier.
13. The method of claim 10 where the platinum compound is carboplatin.
14. The method of claim 7 where the cancer is ovarian 
